{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:32:54Z","timestamp":1791844374547,"version":"4.3.4"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>There are limited data regarding cerebrospinal fluid (CSF) and plasma biomarkers among patients with Cerebral Amyloid Angiopathy (CAA). We sought to investigate the levels of four biomarkers [\u03b2-amyloids (A\u03b242 and A\u03b240), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients compared to healthy controls (HC) and patients with Alzheimer Disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of published studies, including also a 5\u2009year single-center cohort study, with available data on CSF and plasma biomarkers in symptomatic sporadic CAA versus HC and AD was conducted. Biomarkers\u2019 comparisons were investigated using random-effects models based on the ratio of mean (RoM) biomarker concentrations. RoM\u2009&amp;lt;\u20091 and RoM\u2009&amp;gt;\u20091 indicate lower and higher biomarker concentration in CAA compared to another population, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified nine cohorts, comprising 327 CAA patients (mean age: 71\u2009\u00b1\u20095\u2009years; women: 45%) versus 336 HC (mean age: 65\u2009\u00b1\u20095\u2009years; women: 45%) and 384 AD patients (mean age: 68\u2009\u00b1\u20093\u2009years; women: 53%) with available data on CSF biomarkers. CSF A\u03b242 levels [RoM: 0.47; 95% CI: 0.36\u20130.62; p\u2009&amp;lt;\u20090.0001], A\u03b240 levels [RoM: 0.70; 95% CI: 0.63\u20130.79; p\u2009&amp;lt;\u20090.0001] and the ratio A\u03b242\/A\u03b240 [RoM: 0.62; 95% CI: 0.39\u20130.98; p\u2009=\u20090.0438] differentiated CAA from HC. CSF A\u03b240 levels [RoM: 0.73; 95% CI: 0.64\u20130.83; p\u2009=\u20090.0003] differentiated CAA from AD. CSF tau and p-tau levels differentiated CAA from HC [RoM: 1.71; 95% CI: 1.41\u20132.09; p\u2009=\u20090.0002 and RoM: 1.44; 95% CI: 1.20\u20131.73; p\u2009=\u20090.0014, respectively] and from AD [RoM: 0.65; 95% CI: 0.58\u20130.72; p\u2009&amp;lt;\u20090.0001 and RoM: 0.64; 95% CI: 0.57\u20130.71; p\u2009&amp;lt;\u20090.0001, respectively]. Plasma A\u03b242 [RoM: 1.14; 95% CI: 0.89\u20131.45; p\u2009=\u20090.2079] and A\u03b240 [RoM: 1.07; 95% CI: 0.91\u20131.25; p\u2009=\u20090.3306] levels were comparable between CAA and HC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CAA is characterized by a distinct CSF biomarker pattern compared to HC and AD. CSF A\u03b240 levels are lower in CAA compared to HC and AD, while tau and p-tau levels are higher in CAA compared to HC, but lower in comparison to AD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873241260538","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T06:19:13Z","timestamp":1718259553000},"page":"278-288","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review\/meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"given":"Aikaterini","family":"Theodorou","sequence":"first","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Tsantzali","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Ioanna","family":"Stefanou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-1939","authenticated-orcid":false,"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, Via Vetoio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-0023","authenticated-orcid":false,"given":"Aristeidis H","family":"Katsanos","sequence":"additional","affiliation":[{"name":"Division of Neurology, McMaster University\/Population Health Research Institute, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-1626","authenticated-orcid":false,"given":"Ashkan","family":"Shoamanesh","sequence":"additional","affiliation":[{"name":"Division of Neurology, McMaster University\/Population Health Research Institute, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Karapanayiotides","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Aristotle University of Thessaloniki, School of Medicine, AHEPA University Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Koutroulou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Aristotle University of Thessaloniki, School of Medicine, AHEPA University Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Stamati","sequence":"additional","affiliation":[{"name":"Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Werring","sequence":"additional","affiliation":[{"name":"Stroke Research Centre, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"University Lille, Inserm, CHU Lille, U1172, LilNCog, Lille Neuroscience and Cognition, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7757-609X","authenticated-orcid":false,"given":"Lina","family":"Palaiodimou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Zompola","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Boviatsis","sequence":"additional","affiliation":[{"name":"Second Department of Neurosurgery, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lampis","family":"Stavrinou","sequence":"additional","affiliation":[{"name":"Second Department of Neurosurgery, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantzeska","family":"Frantzeskaki","sequence":"additional","affiliation":[{"name":"Second Critical Care Department, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Steiner","sequence":"additional","affiliation":[{"name":"Departments of Neurology, Klinikum Frankfurt H\u00f6chst, Frankfurt and Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei V","family":"Alexandrov","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Arizona, Banner University Medical Center, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios P","family":"Paraskevas","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-3797","authenticated-orcid":false,"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Neurology, University of Tennessee Health Science Center, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"2026012113070818000_bibr1-23969873241260538","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/brain\/awx047","article-title":"Emerging concepts in sporadic cerebral amyloid angiopathy","volume":"140","author":"Charidimou","year":"2017","journal-title":"Brain"},{"key":"2026012113070818000_bibr2-23969873241260538","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1212\/WNL.56.4.537","article-title":"Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria","volume":"56","author":"Knudsen","year":"2001","journal-title":"Neurology"},{"key":"2026012113070818000_bibr3-23969873241260538","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","article-title":"Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy","volume":"74","author":"Linn","year":"2010","journal-title":"Neurology"},{"key":"2026012113070818000_bibr4-23969873241260538","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1161\/STROKEAHA.121.035836","article-title":"Prevalence of clinical and neuroimaging markers in cerebral amyloid angiopathy: a systematic review and meta-analysis","volume":"53","author":"Malhotra","year":"2022","journal-title":"Stroke"},{"key":"2026012113070818000_bibr5-23969873241260538","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.3390\/jcm12175591","article-title":"Clinical characteristics, neuroimaging markers, and outcomes in patients with cerebral amyloid angiopathy: a prospective cohort study","volume":"12","author":"Theodorou","year":"2023","journal-title":"J Clin Med"},{"key":"2026012113070818000_bibr6-23969873241260538","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(23)00114-X","article-title":"Progression of cerebral amyloid angiopathy: a pathophysiological framework","volume":"22","author":"Koemans","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026012113070818000_bibr7-23969873241260538","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0271678X17700435","article-title":"Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage","volume":"38","author":"Xiong","year":"2018","journal-title":"J Cereb Blood Flow Metab"},{"key":"2026012113070818000_bibr8-23969873241260538","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1007\/s00415-023-11977-8","article-title":"Domain-specific neuropsychological investigation of CAA with and without intracerebral haemorrhage","volume":"270","author":"Chan","year":"2023","journal-title":"J Neurol"},{"key":"2026012113070818000_bibr9-23969873241260538","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011631","article-title":"Lacunes, microinfarcts, and vascular dysfunction in cerebral amyloid angiopathy","volume":"96","author":"Gokcal","year":"2021","journal-title":"Neurology"},{"key":"2026012113070818000_bibr10-23969873241260538","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005030","article-title":"Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis","volume":"90","author":"Charidimou","year":"2018","journal-title":"Neurology"},{"key":"2026012113070818000_bibr11-23969873241260538","doi-asserted-by":"crossref","first-page":"783996","DOI":"10.3389\/fnagi.2022.783996","article-title":"Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: new data and quantitative meta-analysis","volume":"14","author":"Margraf","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"2026012113070818000_bibr12-23969873241260538","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276933","article-title":"Patients with Alzheimer\u2019s disease have an increased removal rate of soluble beta-amyloid-42","volume":"17","author":"Zaretsky","year":"2022","journal-title":"PLoS One"},{"key":"2026012113070818000_bibr13-23969873241260538","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3233\/JAD-215208","article-title":"Cerebrospinal fluid profile of tau, phosphorylated tau, a\u03b242, and a\u03b240 in probable cerebral amyloid angiopathy","volume":"87","author":"Grangeon","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"2026012113070818000_bibr14-23969873241260538","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3233\/JAD-170458","article-title":"Plasma amyloid-\u03b2 levels, cerebral small vessel disease, and cognition: the Rotterdam study","volume":"60","author":"Hilal","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2026012113070818000_bibr15-23969873241260538","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/STROKEAHA.117.019810","article-title":"Plasma a\u03b2 (Amyloid-\u03b2) levels and severity and progression of small vessel disease","volume":"49","author":"van Leijsen","year":"2018","journal-title":"Stroke"},{"key":"2026012113070818000_bibr16-23969873241260538","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2026012113070818000_bibr17-23969873241260538","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-328792","article-title":"Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon","author":"Banerjee","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113070818000_bibr18-23969873241260538","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1093\/brain\/awad193","article-title":"Clinical considerations in early-onset cerebral amyloid angiopathy","volume":"146","author":"Banerjee","year":"2023","journal-title":"Brain"},{"key":"2026012113070818000_bibr19-23969873241260538","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2026012113070818000_bibr20-23969873241260538","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2026012113070818000_bibr21-23969873241260538","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2026012113070818000_bibr22-23969873241260538","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026012113070818000_bibr23-23969873241260538","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2026012113070818000_bibr24-23969873241260538","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026012113070818000_bibr25-23969873241260538","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: Ras a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Softw"},{"key":"2026012113070818000_bibr26-23969873241260538","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2026012113070818000_bibr27-23969873241260538","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019","edition":"2nd ed."},{"key":"2026012113070818000_bibr28-23969873241260538","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026012113070818000_bibr29-23969873241260538","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ana.21694","article-title":"Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy","volume":"66","author":"Verbeek","year":"2009","journal-title":"Ann Neurol"},{"key":"2026012113070818000_bibr30-23969873241260538","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/jcbfm.2015.25","article-title":"Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami","volume":"35","author":"Mart\u00ednez-Lizana","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"2026012113070818000_bibr31-23969873241260538","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3233\/JAD-160400","article-title":"Cerebrospinal fluid Alzheimer\u2019s disease biomarkers in isolated supratentorial cortical superficial siderosis","volume":"54","author":"Renard","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2026012113070818000_bibr32-23969873241260538","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3233\/JAD-191254","article-title":"Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy","volume":"74","author":"Banerjee","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"2026012113070818000_bibr33-23969873241260538","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/ana.26610","article-title":"Decreased cerebrospinal fluid amyloid \u03b2 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy","volume":"93","author":"De Kort","year":"2023","journal-title":"Ann Neurol"},{"key":"2026012113070818000_bibr34-23969873241260538","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad159","article-title":"Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy","volume":"5","author":"Sembill","year":"2023","journal-title":"Brain Commun"},{"key":"2026012113070818000_bibr35-23969873241260538","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.2000.tb06361.x","article-title":"Plasma beta-amyloid peptide, transforming growth factor-beta 1, and risk for cerebral amyloid angiopathy","volume":"903","author":"Greenberg","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"2026012113070818000_bibr36-23969873241260538","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000333811","article-title":"Plasma \u03b2-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke","volume":"10","author":"Hernandez-Guillamon","year":"2012","journal-title":"Neurodegener Dis"},{"key":"2026012113070818000_bibr37-23969873241260538","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-021-00911-7","article-title":"Performance of the plasma a\u03b242\/a\u03b240 ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort","volume":"13","author":"Jang","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2026012113070818000_bibr38-23969873241260538","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13195-023-01245-2","article-title":"Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy","volume":"15","author":"de Kort","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"2026012113070818000_bibr39-23969873241260538","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.0000000000003486","article-title":"\u03b2-amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy","volume":"88","author":"van Etten","year":"2017","journal-title":"Neurology"},{"key":"2026012113070818000_bibr40-23969873241260538","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3233\/JAD-220977","article-title":"Cerebrospinal fluid panel of synaptic proteins in cerebral amyloid angiopathy and Alzheimer\u2019s disease","volume":"92","author":"van den Berg","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"2026012113070818000_bibr41-23969873241260538","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.neurobiolaging.2015.06.028","article-title":"Cerebral amyloid angiopathy and its co-occurrence with Alzheimer\u2019s disease and other cerebrovascular neuropathologic changes","volume":"36","author":"Brenowitz","year":"2015","journal-title":"Neurobiol Aging"},{"key":"2026012113070818000_bibr42-23969873241260538","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2026012113070818000_bibr43-23969873241260538","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"2026012113070818000_bibr44-23969873241260538","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s43587-022-00181-4","article-title":"Cerebral amyloid angiopathy is associated with glymphatic transport reduction and time-delayed solute drainage along the neck arteries","volume":"2","author":"Chen","year":"2022","journal-title":"Nat Aging"},{"key":"2026012113070818000_bibr45-23969873241260538","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"2026012113070818000_bibr46-23969873241260538","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"2026012113070818000_bibr47-23969873241260538","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuron.2018.06.003","article-title":"Dendritic Tau in Alzheimer\u2019s disease","volume":"99","author":"Ittner","year":"2018","journal-title":"Neuron"},{"key":"2026012113070818000_bibr48-23969873241260538","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00415-012-6520-8","article-title":"Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria","volume":"259","author":"Renard","year":"2012","journal-title":"J Neurol"},{"key":"2026012113070818000_bibr49-23969873241260538","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jnnp-2016-314697","article-title":"The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice","volume":"88","author":"Banerjee","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873241260538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873241260538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1\/278\/64652035\/23969873241260538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1\/278\/64652035\/23969873241260538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:07:29Z","timestamp":1769018849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/1\/278\/8263602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873241260538","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,1]]},"published":{"date-parts":[[2025,3,1]]}}}